---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-092528"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:40:49.537575+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Invivyd forms SPEAR Study Group with top researchers to test mAbs for Long COVID

## Summary
- SPEAR Study Group includes Drs. Michael Peluso, Amy Proal, David Putrino; will evaluate PEMGARDA and VYD2311.
- Up to 5% of Americans report Long COVID symptoms; no approved treatments exist for the condition.
- PEMGARDA currently authorized only for COVID-19 prophylaxis; not approved for Long COVID treatment.
- Invivyd plans FDA meeting early 3Q 2025 to discuss rapid approval pathways for COVID-19 mAbs.
- Anecdotal reports suggest pemivibart may relieve Long COVID symptoms; rigorous clinical trials are planned.

## SEC filing metadata
- accession: 0000950170-25-092528
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025092528/0000950170-25-092528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025092528/ivvd-20250702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-092528
- JSON: https://secwatch.observer/filing/0000950170-25-092528.json
- Plain text: https://secwatch.observer/filing/0000950170-25-092528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.